Safety and efficacy of Tofacitinib, an oral Janus Kinase inhibitor, up to 36 Months in patients with active Psoriatic Arthritis: data from the third interim analysis of OPAL balance, an Open-Label, long-term extension study

Podobne zapisy

• Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
  od: Nash, P, i wsp.
  Wydane: (2018)
• Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
  od: Peter Nash, i wsp.
  Wydane: (2020-06-01)
• Safety and efficacy of Tofacitnib in patients with active psoriatic arthritis: Interim analysis of OPAL balance, an open-label, long-term extension study
  od: Nash, P, i wsp.
  Wydane: (2020)
• Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
  od: Nash, P, i wsp.
  Wydane: (2021)
• Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance
  od: Nash, P, i wsp.
  Wydane: (2020)